Perrigo Q3 sales slightly beat expectations on market share gains

By Reuters News


Overview

  • Ireland consumer self-care firm's Q3 sales slightly beat analyst expectations

  • Core net sales declined 1.7% yr/yr due to lower consumption and inventory positioning

  • Company announced divestiture of Infant Formula business to sharpen focus on self-care categories


Outlook

  • Perrigo lowers 2026 Core net sales growth outlook to (3.6)% to (2.5)%

  • Company expects 2026 Core adjusted EPS of $2.15 to $2.35

  • Perrigo sees 2026 Core adjusted operating margin of 14.0% to 15.0%


Result Drivers

  • LOWER CONSUMPTION - Co said lower consumption and more cautious retailer inventory positioning ahead of cough and cold season weighed on net sales

  • CONTRACT MANUFACTURING - Lower contract manufacturing volumes contributed to sales decline

  • MARKET SHARE GAINS - Share gains in U.S. Store Brand OTC and key European brands partly offset sales pressures


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Slight Beat*

$989 mln

$987.20 mln (3 Analysts)

Q3 Loss Per Share

$0.10

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Perrigo Company PLC is $16.50, about 5.1% above its November 3 closing price of $15.70

  • The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 4 three months ago


Reuters Recommended Reads

  • Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance

  • Nov 3 - Bayer raises 2026 profit outlook as pharma business beats expectations

  • Nov 3 - Teva profit beats forecasts, raises 2026 revenue estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk